At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,133 enrolled
Drug / intervention
ponesimod +1 moredrug
Likely dose
ponesimod 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating ponesimod and teriflunomide for Multiple Sclerosis. Completed, enrolled 1,133 participants across 162 sites in 28 countries.
Detailed Summary
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesBelarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJun 2015
Primary CompletionMay 2019
TodayJul 2026
First PostedApr 24, 2015
Enrollment StartJun 4, 2015
Primary CompletionMay 16, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.2 years ago
Interventions
ponesimoddrug
film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
teriflunomidedrug
film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning